CHARENTON-LE-PONT, France and SAN RAMON, California—SightGlass Vision, the EssilorLuxottica and CooperCompanies joint venture to develop spectacle lenses to reduce myopia progression in children, is now operational. The two vision care leaders, which have 50/50 ownership of the California-based company, announced yesterday that they have finalized their joint venture agreement signed in February 2021, as VMAIL reported, and that SightGlass Vision products will soon reach the market. SightGlass Vision’s Diffusion Optics Technology incorporates thousands of micro-dots into the lens that softly scatter light to reduce contrast on the retina, which is intended to reduce myopia progression in children.

Spectacles with SightGlass Vision Diffusion Optics Technology are not approved for sale within the U.S.
 
Norbert Gorny, co-chief operating officer at EssilorLuxottica said, “As a global leader with a 30-year track record in myopia research, we have been developing the myopia management category for more than a decade. As such, we are thrilled to see our joint venture with CooperCompanies come to life as SightGlass Vision begins to operate and the first products start to reach the market. Together with eyecare professionals, we will be able to grow awareness about existing solutions and improve access to technologies that can help children today and in their future lives.” 
 
Dan McBride, chief operating officer and general counsel at CooperCompanies said, “We are excited to begin this joint venture with EssilorLuxottica to grow the overall myopia management category. Adding spectacle lenses with SightGlass Vision technology to our portfolio of myopia management products translates into better eyesight and brighter lives for countless children.
 
SightGlass Vision’s commitment to clinically based performance fits well with CooperVision, which has conducted the world’s longest-running myopia management clinical study and is committed to establishing myopia management as a standard of care for affected children,” McBride said.
 
The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people—half the world’s population—will be myopic by 2050, according to the American Academy of Ophthalmology journal, Ophthalmology.
 
Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.